title: [Histone deacetylase inhibitors in the treatment of hematological malignancies].
abstract: Histone deacetylases inhibitors (HDACi) represent a new epigenetic targeting therapy class, which is widely investigated in fundamental research and clinical trials. They are able to restore and increase tumor suppressor genes expression and to play an anti-tumoral activity through numerous targets, which are distributed all over the main differentiation, proliferation and survival cellular pathways. Their use in hematology led to vorinostat (SAHA) and romidepsin approval by FDA for the treatment of refractory cutaneous T-cell lymphomas. Preclinical and preliminary clinical results show a promising antineoplasic activity in most hematologic malignancies. This review will focus on the HDACi recent developments and current investigations, highlighted by recent communications.
authors.affiliation: CHU Estaing, service d'hématologie clinique adulte, Clermont-Ferrand Cedex, France.
authors.forename: Richard
authors.initials: R
authors.lastname: Lemal
authors.forename: Aurélie
authors.initials: A
authors.lastname: Ravinet
authors.forename: Cécile
authors.initials: C
authors.lastname: Moluçon-Chabrot
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Bay
authors.forename: Romain
authors.initials: R
authors.lastname: Guièze
mesh_terms: D044127:Epigenesis, Genetic; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000235:genetics; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D056466:Histone Demethylases / Q000502:physiology; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy
chemical_list: D056572:Histone Deacetylase Inhibitors; D056466:Histone Demethylases